Clinical Trial Update: A First in Human Single Ascending Dose (SAD) Study of ATI-1013 in Healthy Smokers [Phase 1]

View source ↗

Summary

First-in-human Phase 1 single ascending dose study of ATI-1013 in healthy smokers, investigating treatment for Thromboangiitis Obliterans (Buerger's Disease), c…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Thromboangiitis Obliterans

Drugs mentioned

• ATI-1013

Snippet

Sponsor: Antidote Therapeutics, Inc | Conditions: Thromboangiitis Obliterans (Buerger's Disease) | Phase 1 | Status: RECRUITING